Part D Coverage of RA Biologics: Dramatic Out-of-Pocket Cost Variance

Documenti analoghi

• Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
  di: DeJong, Colette, et al.
  Pubblicazione: (2019)
• Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
  di: Yazdany, Jinoos, et al.
  Pubblicazione: (2018)
• Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
  di: DeJong, Colette, et al.
  Pubblicazione: (2020)
• Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
  di: Tseng, Chien-Wen, et al.
  Pubblicazione: (2020)
• Association of Medicare Part D Medication Out-of-Pocket Costs with Utilization of Statin Medications
  di: Karaca-Mandic, Pinar, et al.
  Pubblicazione: (2013)